Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $87.27, for a total value of $34,908.00. Following the sale, the vice president owned 75,274 shares in the company, valued at approximately $6,569,161.98. This represents a 0.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Monday, October 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $90.09, for a total transaction of $36,036.00.
• On Friday, September 12th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $98.42, for a total transaction of $39,368.00.

ANI Pharmaceuticals Stock Performance

NASDAQ:ANIP traded down $0.53 during mid-day trading on Friday, hitting $84.02. The stock had a trading volume of 394,304 shares, compared to its average volume of 370,722. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $99.50. The stock has a market cap of $1.82 billion, a price-to-earnings ratio of -109.12 and a beta of 0.54. The company’s 50 day simple moving average is $92.99 and its 200 day simple moving average is $78.04. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.96 and a current ratio of 2.54.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.30. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm had revenue of $227.81 million for the quarter, compared to analyst estimates of $211.92 million. During the same quarter in the prior year, the company earned $1.34 earnings per share. The business’s revenue for the quarter was up 53.6% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ANIP has been the topic of several research reports. Weiss Ratings upgraded shares of ANI Pharmaceuticals from a “hold (c-)” rating to a “buy (b-)” rating in a report on Monday. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. HC Wainwright boosted their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Finally, Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Buy” and an average price target of $99.29.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ANIP. Arrowstreet Capital Limited Partnership acquired a new position in shares of ANI Pharmaceuticals in the third quarter valued at approximately $32,992,000. Balyasny Asset Management L.P. boosted its position in ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company’s stock worth $26,211,000 after buying an additional 276,233 shares during the period. Rubric Capital Management LP grew its holdings in ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after acquiring an additional 200,998 shares during the last quarter. UBS Group AG increased its position in ANI Pharmaceuticals by 45.8% in the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company’s stock valued at $54,032,000 after acquiring an additional 185,172 shares during the period. Finally, Aberdeen Group plc raised its stake in shares of ANI Pharmaceuticals by 76.1% during the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock valued at $28,059,000 after acquiring an additional 181,134 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.